{"entity":{"id":"nct04422366","kind":"trial","name":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females","aka":[],"tldr":"A phase 3 trial of HPV quadrivalent vaccine in cervical cancer and vulvar cancer, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.","summary":"Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females is a phase 3 interventional study registered as NCT04422366 by Shanghai Bovax Biotechnology Co., Ltd., with 8000 participants planned, started 2020-04-28 and due to reach its primary completion in 2027-09-15. Interventions recorded: 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha), GARDASIL®. Conditions listed: Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN1. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04422366","url":"https://clinicaltrials.gov/study/NCT04422366"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical","vulvar","vaginal","hpv-associated-vulvar-cancer","vaginal-squamous-cell-carcinoma"],"sections":[],"technologies":["hpv-vaccine","interception-vaccination"],"targets":[],"drugs":["hpv-quadrivalent-vaccine"],"companies":["shanghai-bovax-biotechnology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04422366","phase":"3","setting":"A Multicenter,Randomized,Blind and Positive-Controlled Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 20-45 Years","sponsor":"Shanghai Bovax Biotechnology Co., Ltd.","started":"2020-04-28","startedType":"actual","enrolled":8000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04422366/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"hpv-associated-vulvar-cancer","kind":"cancer","name":"HPV-associated vulvar squamous cell carcinoma","route":"/cancers/hpv-associated-vulvar-cancer/"},{"id":"vaginal","kind":"cancer","name":"Vaginal cancer","route":"/cancers/vaginal/"},{"id":"vaginal-squamous-cell-carcinoma","kind":"cancer","name":"Vaginal squamous cell carcinoma (HPV-associated)","route":"/cancers/vaginal-squamous-cell-carcinoma/"},{"id":"vulvar","kind":"cancer","name":"Vulvar cancer","route":"/cancers/vulvar/"}],"technology":[{"id":"interception-vaccination","kind":"technology","name":"Cancer interception vaccines","route":"/technologies/interception-vaccination/"},{"id":"hpv-vaccine","kind":"technology","name":"HPV & HBV vaccination","route":"/technologies/hpv-vaccine/"}],"drug":[{"id":"hpv-quadrivalent-vaccine","kind":"drug","name":"HPV quadrivalent vaccine (types 6, 11, 16 and 18)","route":"/drugs/hpv-quadrivalent-vaccine/"}],"company":[{"id":"shanghai-bovax-biotechnology","kind":"company","name":"Shanghai Bovax Biotechnology","route":"/companies/shanghai-bovax-biotechnology/"}]}}